Replies to post #99912 on Biotech Values

[DewDiligence]

what will all the current SNY enoxaparin reps be doing with themselves? how many will be let go?

Some reps will be let go and some may be reassigned to other products. SNY previously disclosed the intention to maintain a skeleton US salesforce for Lovenox if and only if there is one approved generic. Such a decision is consistent with zipjet’s game-theory analysis in #msg-52652888.

p.s. Thanks for posting about the medicinal chemistry.